References
- Whitty A, Kumaravel G. Between a rock and a hard place? Nat Chem Biol. 2006;2(3):112–118.
- Andrews L, Ralston S, Blomme E, et al. A snapshot of biologic drug development: challenges and opportunities. Hum Exp Toxicol. 2015;34(12):1279–1285.
- Smith AJ. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. J Biomol Screen. 2015;20(4):437–453.
- Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
- Brady K, Webster R. Disposition of biologics. Adv Pharmacol. 2012;63:257–277.
- Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J Drug Target. 2012;20(6):481–501.
- Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15(3):271–290.
- Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29(4):215–239.
- Lu C-T, Zhao Y-Z, Wong H-L, et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014;9:2241–2257.
- Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4). doi:10.1042/BSR20150089.
- Turner KB, Alves NJ, Medintz IL, et al. Improving the targeting of therapeutics with single-domain antibodies. Expert Opin Drug Deliv. 2016;1–10. doi:10.1517/17425247.2016.1133583.
- Wold ED, Axup JY, Brunhilde F-H, et al. Fc-small molecule antibody mimetics. Bioconjug Chem. 2015;26(12):2311–2314.
- Yu K, Liu C, Kim B-G, et al. Synthetic fusion protein design and applications. Biotechnol Adv. 2015;33(1):155–164.
- Nero TL, Morton CJ, Holien JK, et al. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer. 2014;14(4):248–262.
- Gul S, Hadian K. Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays. Expert Opin Drug Discov. 2014;9(12):1393–1404.
- Ambadipudi S, Zweckstetter M. Targeting intrinsically disordered proteins in rational drug discovery. Expert Opin Drug Discov. 2016;11(1):65–77.
- Koski G, Tobin MF, Whalen M. The synergy of the whole: building a global system for clinical trials to accelerate medicines development. Clin Ther. 2014;36(10):1356–1370.
- Ekins S, Waller CL, Bradley MP, et al. Four disruptive strategies for removing drug discovery bottlenecks. Drug Discov Today. 2013;18(5/6):265–271.